New mRNA flu vaccine shows promise in early human trial
NCT ID NCT06602531
First seen Oct 31, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This early-stage study tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza in 212 healthy adults aged 18-80. Participants received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus a placebo. Researchers monitored side effects and measured immune responses to find the safest and most effective dose for further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Tekton Research
Longmont, Colorado, 80501, United States
-
Velocity Clinical Research
La Mesa, California, 91942, United States
-
Velocity Clinical Research
San Bernardino, California, 92408, United States
Conditions
Explore the condition pages connected to this study.